dennd5b Antibody

What is DENND5B and why is it relevant for research?

DENND5B (DENN Domain-Containing Protein 5B) is a guanine nucleotide exchange factor (GEF) that activates RAB39A and/or RAB39B by promoting the exchange of GDP to GTP, converting inactive GDP-bound Rab proteins into their active GTP-bound form . Research relevance stems from:

• Critical role in intracellular transport and membrane trafficking pathways

• Function in Golgi to plasma membrane transport of chylomicron secretory vesicles

• Association with lipid metabolism, obesity resistance, and atherosclerosis in mouse models

• Recently identified role in neurodevelopmental disorders with epilepsy features

• Potential involvement in diabetes combined peripheral artery disease (DM-PAD)

The protein contains several conserved domains including DENN domains, RUN domains that mediate binding to Rab6, and a PLAT domain that interacts with phospholipid bilayers .

What are the optimal sample types for DENND5B antibody applications?

Based on available research data, DENND5B antibodies have been successfully used with:

For optimal results, researchers should consider tissue-specific expression patterns, with the highest DENND5B expression observed in brain tissue followed by varying levels in other tissues .

What are the recommended protocols for detecting DENND5B using Western blot?

For reliable Western blot detection of DENND5B, follow these methodological guidelines:

• Sample preparation:

  • Lyse cells in ice-cold D-PBS without Ca2+ and Mg2+ containing protease inhibitors

  • For tissue samples, homogenize in RIPA buffer with protease inhibitors

• Gel electrophoresis:

  • Use 7-10% SDS-PAGE gels (DENND5B has a calculated MW of 145 kDa)

• Transfer and antibody incubation:

  • Recommended primary antibody dilutions: 1:1000 to 1:2000

  • Validated antibodies include:

    • Rabbit polyclonal anti-DENND5B (PA5-58569, Invitrogen)

    • Rabbit polyclonal anti-DENND5B (HPA038865, Merck)

• Detection and analysis:

  • Use HRP-conjugated anti-rabbit secondary antibody (1:5000-1:10000)

  • Visualize using chemiluminescence

  • GAPDH is recommended as a loading control (mouse monoclonal anti-GAPDH, sc-32233)

Troubleshooting note: When interpreting bands, be aware that DENND5B has multiple isoforms that can appear at different molecular weights.

How can DENND5B antibodies be utilized to study its role in intracellular trafficking pathways?

DENND5B antibodies can enable visualization and quantification of intracellular membrane trafficking through complementary advanced techniques:

Methodological approach:

• Colocalization with Golgi markers:

  • Double immunofluorescence labeling using DENND5B antibody (1:50-1:100) alongside established Golgi markers

  • Confocal microscopy with high-resolution Z-stack imaging

  • Analysis of Pearson's correlation coefficient to quantify colocalization degree

• Live-cell vesicle trafficking assays:

  • Transfect cells with fluorescent-tagged DENND5B constructs

  • Track chylomicron secretory vesicle movement using fluorescent lipid probes:

    • NBD C6-ceramide (catalog #N1154)

    • BODIPY FL C12-sphingomyelin (catalog #D7711)

  • Quantify using high-content imaging systems (e.g., Opera Phenix)

• Golgi-to-plasma membrane transport:

  • Measure fluorescent spot distribution resembling intracellular vesicles

  • Compare wild-type vs. mutant DENND5B effects on trafficking rates

Recent research demonstrated that DENND5B variants impair intracellular vesicle trafficking with significant effects on lipid uptake and distribution, supporting DENND5B's critical role in membrane trafficking pathways .

What are the optimal approaches for studying DENND5B in relation to PCSK9-induced hypercholesterolemia?

Research shows DENND5B-deficient mice are resistant to PCSK9-induced hypercholesterolemia and atherosclerosis, making this an important area of investigation .

Recommended methodological approach:

• Animal model preparation:

  • Use Dennd5b-/- knockout mice and wild-type controls

  • Induce hypercholesterolemia via:

    • AAV-mediated overexpression of PCSK9 gain-of-function variant (D377Y)

    • Western diet feeding (12 weeks protocol)

• Experimental measurements:

  • Monitor plasma lipid concentrations at 0, 2, 4, 8, and 12 weeks post-infection

  • Quantify lipoprotein profiles using FPLC to resolve major lipoprotein classes

  • Assess atherosclerosis via:

    • En face analysis of aortic lesions

    • Aortic root section histological examination

• DENND5B antibody applications:

  • Western blot analysis of liver samples to confirm Dennd5b deletion

  • IHC analysis of aortic sections using anti-DENND5B antibody (1:50-1:100)

  • Co-staining with lipid accumulation markers

Key research findings:
Dennd5b-/- mice showed significantly lower plasma PCSK9-induced cholesterol increase (+128%) compared to wild-type (+500%) . Additionally, Dennd5b-/- mice developed smaller atherosclerotic lesions (3.1% vs 17% lesion area) , suggesting DENND5B as a potential therapeutic target for hypercholesterolemia.

How can researchers investigate the functional consequences of DENND5B variants using antibody-based approaches?

To characterize the functional impact of DENND5B variants (particularly those associated with neurodevelopmental disorders), employ these methodological strategies:

• Expression level analysis:

  • Transfect cells with wild-type and variant DENND5B constructs

  • Quantify protein levels via western blot using validated antibodies

  • Compare expression between wild-type and variant forms

• Subcellular localization studies:

  • Immunofluorescence microscopy comparing wild-type vs. variant localization

  • Co-staining with organelle markers (Golgi, recycling endosomes)

  • Perform quantitative image analysis of colocalization coefficients

• Functional vesicle trafficking assays:

  • Expose cells to fluorescent lipid probes

  • Monitor uptake and intracellular distribution using high-content imaging

  • Quantify parameters including:

    • Number of fluorescent vesicles

    • Vesicle size distribution

    • Trafficking velocity and directionality

Research findings table:
The following data demonstrates differential effects of DENND5B variants on lipid transport:

These findings indicate that DENND5B variants impair intracellular membrane trafficking pathways, confirming their pathogenicity in neurodevelopmental disorders .

What are the critical validation steps for DENND5B antibodies in experimental workflows?

Proper validation is essential for ensuring specificity and reliability of DENND5B antibodies in research:

• Specificity validation:

  • Western blot analysis using wild-type and Dennd5b knockout samples

  • Preabsorption control with immunizing peptide

  • Testing across multiple cell lines with different DENND5B expression levels

  • Cross-reactivity testing in species of interest (human, mouse, etc.)

• Application-specific validation:

  • For WB: Validate appropriate dilution ranges (1:1000 recommended)

  • For IHC: Test multiple fixation conditions and antigen retrieval methods

  • For IF: Compare different permeabilization methods to optimize signal

• Reproducibility assessment:

  • Test multiple antibody lots

  • Include positive and negative controls in each experiment

  • Document experimental conditions comprehensively

Note: Several validated DENND5B antibodies are available including rabbit polyclonal anti-DENND5B (PA5-58569, Invitrogen) and rabbit polyclonal anti-DENND5B (HPA038865, Merck) , which have been documented in published studies.

How can researchers address conflicting data when studying DENND5B using different antibodies?

Inconsistent results across antibodies are common challenges in DENND5B research. Address these methodologically:

• Epitope mapping and analysis:

  • Compare epitope regions of different antibodies:

    • C-terminal region (aa 1066-1094)

    • Middle region antibodies

    • N-terminal antibodies

  • Determine if epitopes might be masked in certain experimental conditions

• Isoform-specific recognition:

  • DENND5B has multiple isoforms (up to 4 reported)

  • Determine which isoforms each antibody detects

  • Correlate with tissue-specific isoform expression patterns

• Systematic comparison approach:

  • Test multiple antibodies side-by-side under identical conditions

  • Document differences in dilution, incubation time, and detection methods

  • Consider using tagged recombinant DENND5B as a control reference

• Resolution strategies:

  • Employ genetic approaches (siRNA, CRISPR) to validate antibody specificity

  • Use orthogonal detection methods (mass spectrometry) to confirm findings

  • Consider alternative approaches like proximity ligation assay for protein interactions

For DENND5B research specifically, comparing antibody performance across brain-derived samples (where expression is highest) versus other tissues can help resolve discrepancies .

How can DENND5B antibodies contribute to understanding neurodevelopmental disorders?

Recent research has identified de novo variants in DENND5B as causative for neurodevelopmental disorders with distinctive features . DENND5B antibodies enable several critical investigative approaches:

• Developmental expression profiling:

  • IHC analysis of DENND5B in developing brain tissues

  • Temporal expression patterns across neurodevelopmental stages

  • Co-staining with neural cell type markers

• Patient-derived sample analysis:

  • Compare DENND5B localization and expression in:

    • Fibroblasts from affected individuals vs. controls

    • iPSC-derived neurons harboring DENND5B variants

  • Correlate protein expression with clinical severity

• Mechanistic studies:

  • Visualize vesicle trafficking abnormalities in neural cells

  • Investigate roles in synaptic transmission

  • Examine effects on myelination processes given white matter abnormalities

Research findings: DENND5B variants have been shown to cause a neurodevelopmental syndrome with cognitive impairment, dysmorphism, abnormal behavior, variable epilepsy, white matter abnormalities, and cortical gyration defects . Immunolocalization studies revealed decreased protein levels of DENND5B mutants in various cell types, with functional investigation showing defective intracellular vesicle trafficking .

What are the most promising applications of DENND5B antibodies in atherosclerosis and metabolic disease research?

DENND5B's role in lipid metabolism positions it as a significant target in metabolic disease research:

• Atherosclerosis progression studies:

  • Use DENND5B antibodies to analyze protein expression in:

    • Atherosclerotic plaques

    • Arterial wall sections

    • Macrophage foam cells

  • Correlate expression with disease severity markers

• Lipid metabolism pathway investigation:

  • Study DENND5B interactions with:

    • PCSK9 signaling components

    • LDL receptor trafficking machinery

    • Hepatic lipid regulatory proteins

  • Quantify colocalization with lipid droplets and chylomicrons

• Therapeutic target validation:

  • Monitor DENND5B expression changes in response to:

    • Lipid-lowering medications

    • Dietary interventions

    • Genetic modifications of metabolic pathways

Research findings: Dennd5b-deficient mice showed resistance to diet-induced weight gain and PCSK9-induced hypercholesterolemia . They exhibited significantly smaller atherosclerotic lesions and reduced hepatic lipid content (triglyceride and cholesterol) . Key genes involved in hepatic lipid metabolism (Pparg, Cd36, Pnpla3) showed differential expression in Dennd5b-/- liver, suggesting DENND5B influences metabolic pathways beyond its role in chylomicron secretion .

What emerging applications exist for DENND5B antibodies in diabetes research?

Recent findings have implicated DENND5B in diabetes combined peripheral artery disease (DM-PAD), opening new research avenues :

• Genetic association validation:

  • Use DENND5B antibodies to analyze protein expression in:

    • Vascular tissues from diabetic patients

    • Animal models of diabetic vascular complications

    • Circulating immune cells from DM-PAD patients

• Mechanistic investigation:

  • Study DENND5B's role in:

    • Endothelial cell function under diabetic conditions

    • Inflammatory signaling pathways in vascular tissues

    • Insulin-responsive trafficking pathways

• Biomarker development:

  • Assess DENND5B as a potential biomarker for:

    • Early detection of vascular complications in diabetes

    • Disease progression monitoring

    • Treatment response prediction

Research findings: Mendelian Randomization and SMR analyses identified DENND5B as a hub gene associated with DM-PAD through mechanisms involving causality rather than mere linkage . COLOC analysis provided strong evidence that DENND5B and the DM-PAD trait were influenced by a common causal variant (rs1150948) . These discoveries highlight DENND5B as a promising target for understanding the molecular basis of diabetic vascular complications.

What experimental controls are essential when using DENND5B antibodies?

Robust experimental design requires appropriate controls to ensure valid interpretation of DENND5B antibody results:

• Negative controls:

  • DENND5B knockout or knockdown samples

  • Secondary antibody-only controls

  • Isotype-matched irrelevant primary antibody

  • Pre-immune serum (for polyclonal antibodies)

• Positive controls:

  • Tissues with known high DENND5B expression (brain samples)

  • Recombinant DENND5B protein

  • Cells overexpressing tagged DENND5B constructs

  • Previously validated samples from published literature

• Specificity controls:

  • Antibody pre-absorption with immunizing peptide

  • Testing in multiple species if cross-reactivity is claimed

  • Parallel testing with multiple DENND5B antibodies targeting different epitopes

• Quantitative controls:

  • Standard curves with recombinant protein for quantitative western blot

  • Housekeeping proteins as loading controls (GAPDH recommended)

  • Concentration-matched IgG controls

Important note: Brain tissue is the most abundant source of DENND5B expression and should be considered the gold standard positive control . For mutant variant studies, including both wild-type and specific variant constructs as controls is essential for comparative analysis .

What considerations should guide the design of DENND5B knockdown/knockout validation experiments?

When designing experiments to validate the specificity of DENND5B antibodies through genetic manipulation:

• Knockdown approach:

  • Use multiple siRNA/shRNA sequences targeting different DENND5B regions

  • Establish dose-response relationships for knockdown efficiency

  • Include scrambled/non-targeting controls

  • Validate knockdown at both mRNA (qPCR) and protein (western blot) levels

• Knockout approach:

  • Consider CRISPR-Cas9 targeting of early exons

  • Design multiple guide RNAs to create frameshift mutations

  • Validate knockout via genomic sequencing, RT-PCR, and western blot

  • Be aware of potential compensatory mechanisms (e.g., DENND5A upregulation)

• Rescue experiments:

  • Re-express wild-type DENND5B in knockout cells

  • Use expression vectors resistant to the knockdown constructs

  • Include functionally relevant assays to confirm phenotype rescue

• Time considerations:

  • Account for DENND5B protein half-life in experimental timeline

  • For inducible systems, establish optimal induction timepoints

  • Consider potential developmental effects in animal models

Research application: Validation experiments have confirmed that DENND5B deficiency leads to differential expression of key genes involved in hepatic lipid metabolism, including Pparg, Cd36, and Pnpla3 , demonstrating the importance of proper validation for downstream functional studies.

How can researchers effectively study DENND5B protein-protein interactions?

DENND5B functions within complex protein interaction networks involving Rab GTPases. These methodological approaches enable detailed interaction studies:

• Co-immunoprecipitation (Co-IP):

  • Use DENND5B antibodies as bait to pull down interacting proteins

  • Recommended protocol:

    • Lyse cells in mild detergent buffer to preserve interactions

    • Pre-clear lysates with protein A/G beads

    • Incubate with DENND5B antibody (2-5 μg per mg of protein)

    • Analyze precipitated complexes by western blot for RAB39A/B, RAB6, etc.

• Proximity ligation assay (PLA):

  • Detect protein interactions in situ with high sensitivity

  • Requires:

    • DENND5B antibody (rabbit host)

    • Interacting protein antibody (different host species)

    • Species-specific PLA probes

    • Quantification of fluorescent spots indicates interaction proximity

• FRET-based approaches:

  • For live-cell interaction studies

  • Create fluorescently tagged constructs of DENND5B and binding partners

  • Measure energy transfer as indication of protein proximity

  • Particularly useful for studying dynamics of Rab GTPase activation

Research insights: Studies indicate DENND5B contains RUN domains that mediate nucleotide-dependent binding to Rab6, crucial for Golgi targeting . The PLAT domain interacts with lipids in recycling endosome membranes, potentially contributing to membrane tethering with Golgi membranes together with RAB11 . These interactions are critical to understanding DENND5B's role in membrane trafficking.

How can researchers visualize DENND5B's role in vesicle trafficking using advanced imaging techniques?

To study DENND5B's dynamic role in vesicle trafficking, these advanced imaging approaches are recommended:

• Live-cell confocal imaging:

  • Transfect cells with fluorescently-tagged DENND5B constructs

  • Label vesicle cargoes with fluorescent markers:

    • NBD C6-ceramide for Golgi

    • BODIPY FL C12-sphingomyelin for plasma membrane

  • Acquire time-lapse sequences (10-15 seconds intervals)

  • Track vesicle movement parameters (velocity, directionality)

• Super-resolution microscopy:

  • STORM or PALM imaging for nanoscale localization

  • Sample preparation:

    • Fix cells with 4% paraformaldehyde

    • Permeabilize with 0.1% Triton X-100

    • Label with primary DENND5B antibody (1:50-1:100)

    • Use compatible super-resolution secondary antibodies

  • Resolve DENND5B localization relative to Golgi subdomains

• High-content screening approach:

  • Automated confocal imaging platform (e.g., Opera Phenix)

  • Quantitative parameters to measure:

    • Number and size of fluorescent vesicles

    • Vesicle distribution relative to Golgi and plasma membrane

    • Colocalization with cargo markers